A61P 27 - Drugs for disorders of the senses

Patents for A61P 27 - Drugs for disorders of the senses (53,017)
10/2002
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083700A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	WO2002083684A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083680A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083184A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	WO2002083178A1 Pharmaceutical composition based on macrolides for topical application in ophthalmology
10/24/2002	WO2002083175A1 Visual function improving agents
10/24/2002	WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083127A1 Protein modification-inhibitory compositions
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083066A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002062386A3 Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156072 Thiazine oxazolidinone
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155115 Cancer therapy
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2444481A1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2443923A1 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443811A1 Type b botulism toxin inhibitors
10/24/2002	CA2443805A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	CA2443733A1 Peptide antiangiogenic drugs
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251131A2 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1250924A1 Eye drops
10/23/2002	EP1250343A1 Azalide antibiotic compositions
10/23/2002	EP1250338A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250133A1 Ophthalmic anti-allergy compositions suitable for use with contact lenses
10/23/2002	EP1250128A2 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
10/23/2002	EP1061943B1 Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
10/23/2002	EP1009380B1 Method for preparing pharmaceutical formulations
10/23/2002	EP0925303B1 Phosphinic acid amides as matrix metalloprotease inhibitors
10/23/2002	EP0923561B1 Heterocyclic metalloprotease inhibitors
10/23/2002	EP0869947B1 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0767170B1 Novel 4,6-diarylpyrimidine derivatives and salts thereof
10/23/2002	CN1376160A Novel macrolide antibiotics
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376054A Topcial suspension formulations containing ciprofloxacin and dexa methasone
10/23/2002	CN1092990C Modulation of cell proliferation and wound healing
10/23/2002	CN1092954C Ophthalamic compositions containing cyclotextrins and quatemary ammonium compound
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469043 Antiangiogenic agent with antitumor, antimetastatic properties which shows high safety
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469020 Hydroxamic and carboxylic acid derivatives
10/22/2002	US6469018 Compounds
10/22/2002	US6469001 IL-5 inhibiting 6-azauracil derivatives
10/22/2002	US6469000 1,3-diheterocyclic metalloprotease inhibitors
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	US6468548 Autoclavable pharmaceutical compositions containing a chelating agent
10/22/2002	US6468519 Polyanhydrides with biologically active degradation products
10/17/2002	WO2002082091A2 Method for identification of proteins from intracellular bacteria
10/17/2002	WO2002081627A2 Methods of screening and using inhibitors of angiogenesis
10/17/2002	WO2002081513A2 Disease-associated protein
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081424A2 Chemical compounds derived from octopamine and their uses as beta 3-adrenergic agonists
10/17/2002	WO2002081420A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof
10/17/2002	WO2002081415A2 Method for inhibiting metap2
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080928A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080915A2 Composition for the treatment of night sight problems (halos, coma and glare) comprising aceclidine
10/17/2002	WO2002080909A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases

1 ... 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 ... 531